Read by QxMD icon Read

Multiple sclerosis drugs

Meng-Na Zhang, Li-Ping Zou, Yang-Yang Wang, Ling-Yu Pang, Shu-Fang Ma, Lu-Lu Huang, Yang Gao, Qian Lu, David Neal Franz
PURPOSE: Tuberous sclerosis (TSC) is an autosomal dominant inherited disease caused by mutations in the TSC1 or TSC2 gene and results in the over-activation of the mammalian target of the rapamycin (mTOR) signaling pathway. Rapamycin, an mTOR inhibitor, is clinically used to treat hamartomatous lesionsas in TSC and its effect on controlling epilepsy is also reported in many studies. This study aims to evaluate the risk factors of pharmacoresistant epilepsy in patients with TSC receiving long-term rapamycin treatment...
June 15, 2018: Seizure: the Journal of the British Epilepsy Association
Roya Abolfazli, Shirin Pournourmohammadi, Ahmadreza Shamshiri, Sara Samadzadeh
Background: The aim of this study was to evaluate the safety, tolerability, and efficacy of a brand-generic glatiramer acetate product in patients with relapsing-remitting multiple sclerosis over a 12-month period. A noninterventional cohort study was conducted on 185 patients. The patients had a confirmed and documented diagnosis of relapsing-remitting multiple sclerosis as defined by the Revised McDonald Criteria (2010), were ambulatory with a Kurtzke Expanded Disability Status Scale score of 0 to 5...
2018: Current Therapeutic Research, Clinical and Experimental
Nastaran Majdinasab, Foroogh Namjoyan, Mohsen Taghizadeh, Hamid Saki
Background: Multiple sclerosis (MS) is a chronic progressive and inflammatory disease of the central nervous system that is characterized by demyelination in the central nervous system. In regard to the prevalence of diseases and enormous costs imposed on society and the health system, finding a way to stop the progression of the disease using drugs with fewer side effects seems a serious sanitation issue to the health of the international community. This study aimed to evaluate the effect of evening primrose oil (EPO) on fatigue and quality of life in patients with MS...
2018: Neuropsychiatric Disease and Treatment
Ariana Helena Ribeiro de Barros, João Paulo Fiadeiro Sequeira, Ary Severino Lopes de Sousa, Carlos Miguel Cheganças Capela, Rui Manuel Gomes Pedrosa, Manuel Alexandre Dos Santos Manita
OBJECTIVES: The aim of this study was to evaluate postmarketing fingolimod safety and effectiveness in a real-world clinical population. METHODS: This was a retrospective, single-center study with active multiple sclerosis patients treated with fingolimod with at least 12 months of follow-up. Demographic and clinical and imaging characteristics, including annualized relapse rate (ARR), Expanded Disability Status Score, previous treatment, adverse events, treatment duration, and reason for discontinuation, were analyzed...
June 20, 2018: Clinical Neuropharmacology
Karen Lariosa-Willingham, Dmitri Leonoudakis
Multiple sclerosis (MS) is an autoimmune disease that involves an immune-mediated inflammatory response in the central nervous system and optic nerve resulting in demyelination and neural degeneration, the cause of which is unknown. The adult central nervous system has the capacity to remyelinate axons by generating new oligodendrocytes (OLs). To identify clinical candidate compounds that may promote remyelination, we have developed a high-throughput screening (HTS) assay to identify compounds that promote the differentiation of oligodendrocyte precursor cells (OPCs) into OLs...
June 2018: Current Protocols in Cell Biology
Moussa A Chalah, Samar S Ayache
Purpose: Among autoimmune diseases of the central nervous system stands multiple sclerosis (MS), which is characterized by demyelination, synaptopathy, and neurodegeneration. MS fatigue can affect up to 90% of patients and be very disabling, with a drastic impact on their quality of life. To date, the evaluation of MS fatigue has relied mainly on subjective scales, and actual therapeutic interventions are challenged by modest efficacy and numerous undesirable effects. Therefore, finding biomarkers of MS fatigue might help in optimizing evaluation and treatment strategies...
2018: Journal of Inflammation Research
Frederike C Oertel, Joachim Havla, Adriana Roca-Fernández, Nathaniel Lizak, Hanna Zimmermann, Seyedamirhosein Motamedi, Nadja Borisow, Owen B White, Judith Bellmann-Strobl, Philipp Albrecht, Klemens Ruprecht, Sven Jarius, Jacqueline Palace, Maria Isabel Leite, Tania Kuempfel, Friedemann Paul, Alexander U Brandt
OBJECTIVES: Neuromyelitis optica spectrum disorders (NMOSD) are inflammatory conditions of the central nervous system and an important differential diagnosis of multiple sclerosis (MS). Unlike MS, the course is usually relapsing, and it is unclear, if progressive neurodegeneration contributes to disability. Therefore, we aimed to investigate if progressive retinal neuroaxonal damage occurs in aquaporin4-antibody-seropositive NMOSD. METHODS: Out of 157 patients with NMOSD screened, 94 eyes of 51 patients without optic neuritis (ON) during follow-up (F/U) and 56 eyes of 28 age-matched and sex-matched healthy controls (HC) were included (median F/U 2...
June 19, 2018: Journal of Neurology, Neurosurgery, and Psychiatry
Zahid Rasul Niazi, Naqab Khan, Samiullah Khan, Mehboob Alam, Mohammad A Kamal
BACKGROUND: Neurodegenerative disorder are persistently increasing and relentlessly affecting the individuals, families and society as whole. Regrettably these disorders are resistant to the available drugs, the outcomes are only palliative while the side effects of the therapy harm the patient compliance as well as treatment. Drugs from venomous source have been considered as an effective alternative for such types of disorders, particularly neurodegenerative diseases. Due to emerging advancement in the field of proteomics, genomics and molecular biology, characterization and screening of these novel compounds become more assessable...
June 14, 2018: Protein and Peptide Letters
Alejandro Ruiz-Argüelles, Jose M Gastélum-Cano, Mariana A Méndez-Huerta, Alma B Rodríguez-Gallegos, Guillermo J Ruiz-Argüelles
Background: Glomerular filtration rate (GFR) is partially impaired in patients with multiple sclerosis (MS). When given chemotherapy before receiving hematopoietic stem-cell transplantation, GFR might be further deteriorated. Objective: To measure the effect of cyclophosphamide on GFR in patients with MS who undergo chemotherapy. Methods: We estimated GFR based on creatinine and cystatin C plasma concentrations in patients undergoing autologous hematopoietic stem-cell transplantation to treat their MS...
June 15, 2018: Laboratory Medicine
Salaheddin M Mahmud, Songul Bozat-Emre, Luiz C Mostaço-Guidolin, Ruth Ann Marrie
To investigate a potential risk for multiple sclerosis (MS) after vaccination with Arepanrix, the GlaxoSmithKline AS03-adjuvanted influenza A(H1N1)pdm09 vaccine, we used the provincewide immunization registry for Manitoba, Canada, to match 341,347 persons vaccinated during the 2009 pandemic to 485,941 unvaccinated persons on age, sex, address, and a propensity score measuring the probability of vaccination. We used a previously validated algorithm to identify MS cases from provincial hospital, physician, and prescription drug claims databases...
July 2018: Emerging Infectious Diseases
M A Piena, M Heisen, L W Wormhoudt, J van Wingerden, S T F M Frequin, B M J Uitdehaag
AIM: In active relapsing remitting multiple sclerosis (RRMS) patients requiring second-line treatment, the Dutch National Health Care Institute (ZiN) has not stated a preference for either alemtuzumab, fingolimod or natalizumab. Our aim was to give healthcare decision-makers insight into the differences in cost accumulation over time between alemtuzumab - with a unique, non-continuous treatment schedule - and fingolimod and natalizumab for second-line treatment of active RRMS patients in the Netherlands...
June 18, 2018: Journal of Medical Economics
Heidi M Munger Clary, Beverly M Snively, Marla J Hamberger
OBJECTIVE: The objective of this study was to assess for independent association of anxiety symptoms with epilepsy localization and other epilepsy-related and demographic factors in a large tertiary care adult epilepsy population. METHODS: Among 540 adults, anxiety was measured by the Symptom Checklist 90-R (SCL-90R) anxiety subscale, and detailed demographics, epilepsy localization, and depression scores (SCL-90R) were collected. High anxiety was defined by SCL-90R anxiety T-score ≥ 60...
June 13, 2018: Epilepsy & Behavior: E&B
A Khamidulla, G Kabdrakhmanova, A Utepkaliyeva, D Darin, Zh Urasheva
Multiple sclerosis is a chronic dysimmune neurodegenerative disease of the central nervous system, that affects people of working age and inevitably leads to disability. Treatment of the disease is one of the urgent problems of modern clinical neurology, which is explained by the variety of clinical variants of the flow, the lack of an effective method of treatment. This article is devoted to a review of modern approaches to the issues of etiology, pathogenesis and treatment of multiple sclerosis. Also, the classification of multiple sclerosis depending on the course of the disease, data on modern approaches to the treatment of multiple sclerosis, the criteria for the appointment of differentiated therapy depending on the course of the disease with the use of Disease-Modifying Drugs (DMDs) are given...
May 2018: Georgian Medical News
A Juanatey, L Blanco-Garcia, N Tellez
INTRODUCTION: Ocrelizumab is a humanised monoclonal antibody that targets the CD20 antigen on B cells. It has recently been approved by the US (Food and Drug Administration) and European health agencies (European Medicines Agency) for the treatment of multiple sclerosis (MS) and is the first drug marketed for both relapsing-remitting MS (RRMS) and primary progressive MS (PPMS). The clinical trials conducted for both the relapsing forms (OPERA I/II) and the progressive forms of the disease (ORATORIO) have demonstrated its efficacy...
June 16, 2018: Revista de Neurologia
F Castillo-Álvarez, P Pérez-Matute, J A Oteo, M E Marzo-Sola
INTRODUCTION: The association between gut microbiota and animal models of multiple sclerosis has been well established; however, studies in humans are scarce. METHODS: We performed a descriptive, cross-sectional study comparing the relative composition of gut microbiota in 30 patients with multiple sclerosis (15 treated with interferon β-1b, 15 not receiving this treatment) and 14 healthy controls using next generation sequencing. RESULTS: Patients with multiple sclerosis and controls showed differences in the proportion of Euryarchaeota, Firmicutes, Proteobacteria, Actinobacteria, and Lentisphaerae phyla and in 17 bacterial species...
June 9, 2018: Neurología: Publicación Oficial de la Sociedad Española de Neurología
J L López-Estebaranz, P de la Cueva-Dobao, C de la Torre Fraga, M Galán Gutiérrez, E González Guerra, J Mollet Sánchez, I Belinchón Romero
BACKGROUND: There is currently little information available on the management of patients with psoriasis in the daily clinical practice of dermatologists in Spain. OBJECTIVE: The aim of this study was to survey a group of Spanish dermatologists with particular expertise in the management of psoriasis to determine their opinions on the protocols used in routine clinical practice. MATERIAL AND METHODS: A cross-sectional study based on an online survey about the management of psoriasis sent to 75 dermatologists...
June 8, 2018: Actas Dermo-sifiliográficas
K Pape, F Zipp, S Bittner
The spectrum of therapeutic options for immunotherapy of multiple sclerosis is continuously broadening. After the approval of cladribine and ocrelizumab in Europe, two new drugs are now available with ocrelizumab being the first approved option for treatment of primary progressive multiple sclerosis; however, the increased use of highly effective therapies is accompanied by a rise in severe side effects. During recent months, special attention was paid to the new progressive multifocal leukoencephalopathy (PML) risk assessment in natalizumab-treated patients, cardiac side effects of fingolimod, cases of idiopathic thrombocytopenic purpura and listeria meningitis associated with alemtuzumab and cases of daclizumab-treated patients with liver failure or encephalitis...
June 7, 2018: Der Nervenarzt
Seyed Shahabeddin Mortazavi-Jahromi, Mahsa Taeb, Salvatore Cuzzocrea, Emanuela Esposito
BACKGROUND: Nonsteroidal anti-inflammatory drugs (NSAIDs) are used to treat the pathological pain and inflammation through inhibition of cyclooxygenase (COX) enzyme and disruption of the synthesis of prostaglandins (PGs). The α-L-guluronic acid (G2013) patented (PCT/EP2017/067920), as a novel NSAID with the immunomodulatory property, has been shown its positive effects in experimental models of multiple sclerosis and anti-aging. OBJECTIVE: This study was aimed to investigate the effects of G2013 on the gene expression and activity of COX-1/COX-2 enzymes in order to introduce a novel NSAID for the treatment of inflammatory diseases...
June 7, 2018: Recent Patents on Inflammation & Allergy Drug Discovery
Nadia Pariani, Mark Willis, Ilaria Muller, Sarah Healy, Taha Nasser, Anne McGowan, Greta Lyons, Joanne Jones, Krishna Chatterjee, Colin Dayan, Neil Robertson, Alasdair Coles, Carla Moran
Context: Alemtuzumab, a highly effective treatment for multiple sclerosis (MS), predisposes to Graves' disease (GD) with a reportedly indolent course. Objective: To determine the type, frequency and course of thyroid dysfunction (TD) in a cohort of alemtuzumab-treated MS patients in the UK. Design: Case records of alemtuzumab-treated patients who developed TD were reviewed. Results: 41.1% (102/248; 80F, 22M) of patients developed TD, principally GD (71...
June 6, 2018: Journal of Clinical Endocrinology and Metabolism
Marsilio Adriani, Petra Nytrova, Cyprien Mbogning, Signe Hässler, Karel Medek, Poul Erik H Jensen, Paul Creeke, Clemens Warnke, Kathleen Ingenhoven, Bernhard Hemmer, Claudia Sievers, Raija Lp Lindberg Gasser, Nicolas Fissolo, Florian Deisenhammer, Zsolt Bocskei, Vincent Mikol, Anna Fogdell-Hahn, Eva Kubala Havrdova, Philippe Broët, Pierre Dönnes, Claudia Mauri, Elizabeth C Jury
Multiple sclerosis (MS) is an autoimmune disease characterized by CNS inflammation leading to demyelination and axonal damage. IFN-β is an established treatment for MS; however, up to 30% of IFN-β-treated MS patients develop neutralizing antidrug antibodies (nADA), leading to reduced drug bioactivity and efficacy. Mechanisms driving antidrug immunogenicity remain uncertain, and reliable biomarkers to predict immunogenicity development are lacking. Using high-throughput flow cytometry, NOTCH2 expression on CD14+ monocytes and increased frequency of proinflammatory monocyte subsets were identified as baseline predictors of nADA development in MS patients treated with IFN-β...
June 7, 2018: JCI Insight
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"